CA2086565A1 - Pharmaceutical composition for treating pigmentation - Google Patents
Pharmaceutical composition for treating pigmentationInfo
- Publication number
- CA2086565A1 CA2086565A1 CA002086565A CA2086565A CA2086565A1 CA 2086565 A1 CA2086565 A1 CA 2086565A1 CA 002086565 A CA002086565 A CA 002086565A CA 2086565 A CA2086565 A CA 2086565A CA 2086565 A1 CA2086565 A1 CA 2086565A1
- Authority
- CA
- Canada
- Prior art keywords
- cheeks
- improved
- pharmaceutical composition
- forehead
- pigmentation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/676—Ascorbic acid, i.e. vitamin C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Birds (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
ABSTRACT OF THE DISCLOSURE
A pharmaceutical composition for treating pigmentation for internal use which contains tranexamic acid and ascorbic acid or a salt thereof is disclosed. The composition is useful for treating pigmentation in a short time when orally administered.
A pharmaceutical composition for treating pigmentation for internal use which contains tranexamic acid and ascorbic acid or a salt thereof is disclosed. The composition is useful for treating pigmentation in a short time when orally administered.
Description
20g~
PHARMACEUTICAL COMPOSITION FOR TREATING PIGMENTATION
FIELD OF THE INVENTION
This invention relates to a pharmaceutical composition for internal use having a remarkable effect on pigmentation.
BACKGROUND OF THE INVENTION
Pigmentation is considered to ensue from chromatism of melanin in the skin generally caused by heredity, endocrinosis, stimulation by ultraviolet rays of sunlight, skin irritation by photodynamic substances, etc., aggravation of allergodermia, and so on.
Conventionally proposed treatment for pigmentation includes drugs for external use containing hydroquinone, vitamin C
derivatives, kojic acid, tranexamic acid, etc. and drugs for internal use containing vitamin C, L-cysteine, glutathione, tranexamic acid, etc. Some of these drugs have already been on the market, but no drugs except hydroquinone preparations shows a sufficient effect in a short time. However, hydroquinone preparations have hardly been used due to their strong side effects.
SUMMARY OF THE INVENTION
Accordingly, an object of the present invention is to provide a pharmaceutical composition for treating pigmentation which is of high safety with freedom from side effects and is expected to produce a sufficient effect through short-term administration.
- 2as6,~J~
In the light of the above-mentioned circumstances, the inventors have conducted extensive investigations and, as a result, have found that a combination of tranexamic acid which is noted to have efficacy to some extent when orally administered alone and ascorbic acid or a salt thereof which has no discernible effect when administered alone exerts a synergistically enhanced effect in the treatment of pigmentation and produces high therapeutic effects through short-term administration.
The present invention provides a pigmentation treating pharmaceutical composition for internal use which comprises tranexamic acid and ascorbic acid or a salt thereof. ~-DETAILED DESCRIPTION OF THE INVENTION
Tranexamic acid, one of the essential ingredients of the pharmaceutical composition of the present invention, is used as an antiplasmin agent and has such very low toxicity as having an LD50 of not less than 5 g~kg in dogs (p.o.).
Ascorbic acid, the other ingredient, is also of low toxicity as having an LD50 Of not less than 5 g/kg in doqs ~ -(p.o.). Suitable salts of ascorbic acid include a sodium salt and a calcium salt. -~
In the pharmaceutical composition of the present invention, ascorbic acid is contained in an amount of 0.3 to 2 parts by weight, preferably 0.5 to 2 parts by weight, per part by weight of tranexamic acid.
~` ` ~ ''' ~;!.!' ` . , ~ 2~62)65 The pigmentation treating composition of the present invention is preferably orally administered so that each of tranexamic acid and ascorbic acid or its salt be administered at a dose of from 500 to lS00 mg, particularly from 1000 to 1500 mg, per day in a single dose or several divided doses, particularly three divided doses.
The pigmentation treating composition may be formulated into various preparation forms for oral administration, such as granules, particles, powders, capsules, tablets, solutions, and the like together with a pharmaceutically acceptable carrier.
These preparations can be prepared in a usual manner from the above-mentioned essential ingredients, if necessary in ,. .... . .
con~unction with ad~uvants commonly employed in the art and other drugs.
The present invention is now illustrated in greater detail -with reference to Examples, but it should be understood that the present invention is not deemed to be limited thereto.
EXAMPLE 1 - ;
Ascorbic acid 1000 mg Tranexamic acid 1000 mg Powder sugar 2475 mg Light anhydrous silicic acid 25 mg Granules were prepared from the above ingredients in a usual manner and divided into three doses for one day.
PHARMACEUTICAL COMPOSITION FOR TREATING PIGMENTATION
FIELD OF THE INVENTION
This invention relates to a pharmaceutical composition for internal use having a remarkable effect on pigmentation.
BACKGROUND OF THE INVENTION
Pigmentation is considered to ensue from chromatism of melanin in the skin generally caused by heredity, endocrinosis, stimulation by ultraviolet rays of sunlight, skin irritation by photodynamic substances, etc., aggravation of allergodermia, and so on.
Conventionally proposed treatment for pigmentation includes drugs for external use containing hydroquinone, vitamin C
derivatives, kojic acid, tranexamic acid, etc. and drugs for internal use containing vitamin C, L-cysteine, glutathione, tranexamic acid, etc. Some of these drugs have already been on the market, but no drugs except hydroquinone preparations shows a sufficient effect in a short time. However, hydroquinone preparations have hardly been used due to their strong side effects.
SUMMARY OF THE INVENTION
Accordingly, an object of the present invention is to provide a pharmaceutical composition for treating pigmentation which is of high safety with freedom from side effects and is expected to produce a sufficient effect through short-term administration.
- 2as6,~J~
In the light of the above-mentioned circumstances, the inventors have conducted extensive investigations and, as a result, have found that a combination of tranexamic acid which is noted to have efficacy to some extent when orally administered alone and ascorbic acid or a salt thereof which has no discernible effect when administered alone exerts a synergistically enhanced effect in the treatment of pigmentation and produces high therapeutic effects through short-term administration.
The present invention provides a pigmentation treating pharmaceutical composition for internal use which comprises tranexamic acid and ascorbic acid or a salt thereof. ~-DETAILED DESCRIPTION OF THE INVENTION
Tranexamic acid, one of the essential ingredients of the pharmaceutical composition of the present invention, is used as an antiplasmin agent and has such very low toxicity as having an LD50 of not less than 5 g~kg in dogs (p.o.).
Ascorbic acid, the other ingredient, is also of low toxicity as having an LD50 Of not less than 5 g/kg in doqs ~ -(p.o.). Suitable salts of ascorbic acid include a sodium salt and a calcium salt. -~
In the pharmaceutical composition of the present invention, ascorbic acid is contained in an amount of 0.3 to 2 parts by weight, preferably 0.5 to 2 parts by weight, per part by weight of tranexamic acid.
~` ` ~ ''' ~;!.!' ` . , ~ 2~62)65 The pigmentation treating composition of the present invention is preferably orally administered so that each of tranexamic acid and ascorbic acid or its salt be administered at a dose of from 500 to lS00 mg, particularly from 1000 to 1500 mg, per day in a single dose or several divided doses, particularly three divided doses.
The pigmentation treating composition may be formulated into various preparation forms for oral administration, such as granules, particles, powders, capsules, tablets, solutions, and the like together with a pharmaceutically acceptable carrier.
These preparations can be prepared in a usual manner from the above-mentioned essential ingredients, if necessary in ,. .... . .
con~unction with ad~uvants commonly employed in the art and other drugs.
The present invention is now illustrated in greater detail -with reference to Examples, but it should be understood that the present invention is not deemed to be limited thereto.
EXAMPLE 1 - ;
Ascorbic acid 1000 mg Tranexamic acid 1000 mg Powder sugar 2475 mg Light anhydrous silicic acid 25 mg Granules were prepared from the above ingredients in a usual manner and divided into three doses for one day.
2~8~
A simple comparative clinical test was carried out as follows.
The medication prepared in Example 1 (A), tranexamic acid alone (B), or ascorbic acid alone (C) was orally administered to patients (all female) suffering from chloasma, a kind of pigmentation, three times a day for 2 months, and the degrees of pigmentation before and after the administration were ~ ~
compared. ~ :
Inaredients of Daily Dose (3 doses):
Medication _ Inaredient (A) (B~ (C) Ascorbic acid 1000 mg - 1000 mg ~ .
Tranexamic acid1000 mg1500 mg Powder sugar 2475 mg 2975 mg 3475 mg Light anhydrous2S mg 25 mg 25 mg silicic acid The changes in the clinical picture after the administration of the medication are shown in Tables 1 (group ~ : `-`.
on (A)), 2 (group on (B)), and 3 (group on (C)), and the -. - -:: -- .-. ~
ameliorating effect of each medication on pigmentation judged from these clinical pictures is shown in Table 4.
The clinical pictures were allocated in accordance with the following five levels. : .
4: bad (observed through heavy makeup) 3: baddish (covered by heavy makeup) .
2: slight (covered by normal makeup) ?
208G~
1: very slight (covered by light makeup) 0: none In Tables 1 through 3, the degree of improvement was evaluated as follows.
markedly improved: the symptom at any level was improved up to 0 (4~0, 3~0, 2~0, 1~0).
improved: the level of clinical picture was raised by two or three steps (4~2, 4~1, 3~1). .
slightly improved: the level of clinical picture was raised by one step (4~3, 3~2, 2~
unchanged: the clinical picture was unchanged (4~4, 3~3, 2~2, 1~
aggravated: the clinical picture got worse (3~4; 2~3 or 4;
1~2, 3 or 4; 0~1,2,3 or 4) ';
_ 5 _ 2a~&~us Patient GrouP on ~A!
Degree of Case Aqe Sites _Improvement 1 39 forehead, right cheekmarkedly improved 2 39 cheeks, below nose 3 45 cheeks, below nose 4 41 cheeks improved S 31 cheeks ~ :-6 38 cheeks, eyelids ~ `
7 49 cheeks, eyelids -:.
8 40 upper lip 9 40 forehead slightly improved ~;
right cheek improved ..
ll 50 cheeks unchanged 12 47 forehead, cheeksslightly improved 13 52 cheeks unchanged 14 45 forehead, cheeksslightly improved 39 cheeks 16 40 forehead, cheeks improved 17 43 forehead, cheeksslightly improved 18 30 forehead, cheeks improved 19 41 entire face 51 cheeks "
. - - - , , i ~ ~
. ' ~ .
'~ ~
:` ' ' ` ~ :
' " ' .'' I ' , " ~
2v8~ ~
Patient Grou~ on (B) Degree of Case Aqe _ Sites ImProvement 21 45 cheeks improved 22 53 che~ks unchanged 23 58 forehead, left cheekslightly improved 24 43 forehead, cheeks ~
forehead, cheeks improved 26 35 cheeks markedly improved `~
27 38 cheeks improved 28 40 cheeks 29 50 right cheek slightly improved 39 forehead, cheeks improved 31 47 forehead, cheeks unchanged 32 45 cheeks 33 39 cheeks improved 34 40 forehead, cheeks 37 cheeks slightly improved 36 30 forehead improved 37 41 entire face unchanged 38 33 cheeks improved 39 40 cheeks "
37 cheeks slightly improved ,:
-2 0 ~ C~3 Patient GrouP on (C~
Degree of Case Aqe Sites Improvement 41 46 cheeks unchanged ~ . ~
42 43 cheeks 43 38 cheeks slightly improved ~ ~
44 49 forehead, cheeks unchanged - ; -forehead, cheeks 46 37 forehead slightly improved 47 35 cheeks "
48 51 entire face unchanged 49 53 forehead, cheeks 46 cheeks improved :~
51 48 cheeks unchanged :
52 37 right cheek 53 33 forehead slightly improved :
54 39 cheeks, below noseunchanged 37 cheeks improved 56 41 cheeks unchanged ::
57 38 cheeks slightly improved 58 40 left cheek unchanged 59 42 forehead, cheeks 39 forehead, cheeks :, . .
:, ~ - i . ' ~ :,,, ' `
2 9 8 ~ .S
Medication '. ;
Marked Improvement 3 1 0 -Improvement 10 10 2 :
Slight Improvement 5 5 5 : -~
. , :
No Change 2 4 13 Aggravation 0 0 0 _______________________________________________________ Total 20 20 20 Percent Improvement (%) 65.0 55.0 10.0 (90.0~) (80.0~) (35.0 Note: * The value in the parentheses is the percent improvement inclusive of slight improvement.
As described and demonstrated above, the pigmentation treating aqent according to the present invention has high efficacy in treating pigmentation through short-term oral administration without causing any adverse side effect.
While the invention has been described in detail and with reference to specific examples thereof, it will be apparent to one skilled in the art that various changes and modifications can be made therein without departing from the spirit and scope :
thereof.
.
_ g , ~...
A simple comparative clinical test was carried out as follows.
The medication prepared in Example 1 (A), tranexamic acid alone (B), or ascorbic acid alone (C) was orally administered to patients (all female) suffering from chloasma, a kind of pigmentation, three times a day for 2 months, and the degrees of pigmentation before and after the administration were ~ ~
compared. ~ :
Inaredients of Daily Dose (3 doses):
Medication _ Inaredient (A) (B~ (C) Ascorbic acid 1000 mg - 1000 mg ~ .
Tranexamic acid1000 mg1500 mg Powder sugar 2475 mg 2975 mg 3475 mg Light anhydrous2S mg 25 mg 25 mg silicic acid The changes in the clinical picture after the administration of the medication are shown in Tables 1 (group ~ : `-`.
on (A)), 2 (group on (B)), and 3 (group on (C)), and the -. - -:: -- .-. ~
ameliorating effect of each medication on pigmentation judged from these clinical pictures is shown in Table 4.
The clinical pictures were allocated in accordance with the following five levels. : .
4: bad (observed through heavy makeup) 3: baddish (covered by heavy makeup) .
2: slight (covered by normal makeup) ?
208G~
1: very slight (covered by light makeup) 0: none In Tables 1 through 3, the degree of improvement was evaluated as follows.
markedly improved: the symptom at any level was improved up to 0 (4~0, 3~0, 2~0, 1~0).
improved: the level of clinical picture was raised by two or three steps (4~2, 4~1, 3~1). .
slightly improved: the level of clinical picture was raised by one step (4~3, 3~2, 2~
unchanged: the clinical picture was unchanged (4~4, 3~3, 2~2, 1~
aggravated: the clinical picture got worse (3~4; 2~3 or 4;
1~2, 3 or 4; 0~1,2,3 or 4) ';
_ 5 _ 2a~&~us Patient GrouP on ~A!
Degree of Case Aqe Sites _Improvement 1 39 forehead, right cheekmarkedly improved 2 39 cheeks, below nose 3 45 cheeks, below nose 4 41 cheeks improved S 31 cheeks ~ :-6 38 cheeks, eyelids ~ `
7 49 cheeks, eyelids -:.
8 40 upper lip 9 40 forehead slightly improved ~;
right cheek improved ..
ll 50 cheeks unchanged 12 47 forehead, cheeksslightly improved 13 52 cheeks unchanged 14 45 forehead, cheeksslightly improved 39 cheeks 16 40 forehead, cheeks improved 17 43 forehead, cheeksslightly improved 18 30 forehead, cheeks improved 19 41 entire face 51 cheeks "
. - - - , , i ~ ~
. ' ~ .
'~ ~
:` ' ' ` ~ :
' " ' .'' I ' , " ~
2v8~ ~
Patient Grou~ on (B) Degree of Case Aqe _ Sites ImProvement 21 45 cheeks improved 22 53 che~ks unchanged 23 58 forehead, left cheekslightly improved 24 43 forehead, cheeks ~
forehead, cheeks improved 26 35 cheeks markedly improved `~
27 38 cheeks improved 28 40 cheeks 29 50 right cheek slightly improved 39 forehead, cheeks improved 31 47 forehead, cheeks unchanged 32 45 cheeks 33 39 cheeks improved 34 40 forehead, cheeks 37 cheeks slightly improved 36 30 forehead improved 37 41 entire face unchanged 38 33 cheeks improved 39 40 cheeks "
37 cheeks slightly improved ,:
-2 0 ~ C~3 Patient GrouP on (C~
Degree of Case Aqe Sites Improvement 41 46 cheeks unchanged ~ . ~
42 43 cheeks 43 38 cheeks slightly improved ~ ~
44 49 forehead, cheeks unchanged - ; -forehead, cheeks 46 37 forehead slightly improved 47 35 cheeks "
48 51 entire face unchanged 49 53 forehead, cheeks 46 cheeks improved :~
51 48 cheeks unchanged :
52 37 right cheek 53 33 forehead slightly improved :
54 39 cheeks, below noseunchanged 37 cheeks improved 56 41 cheeks unchanged ::
57 38 cheeks slightly improved 58 40 left cheek unchanged 59 42 forehead, cheeks 39 forehead, cheeks :, . .
:, ~ - i . ' ~ :,,, ' `
2 9 8 ~ .S
Medication '. ;
Marked Improvement 3 1 0 -Improvement 10 10 2 :
Slight Improvement 5 5 5 : -~
. , :
No Change 2 4 13 Aggravation 0 0 0 _______________________________________________________ Total 20 20 20 Percent Improvement (%) 65.0 55.0 10.0 (90.0~) (80.0~) (35.0 Note: * The value in the parentheses is the percent improvement inclusive of slight improvement.
As described and demonstrated above, the pigmentation treating aqent according to the present invention has high efficacy in treating pigmentation through short-term oral administration without causing any adverse side effect.
While the invention has been described in detail and with reference to specific examples thereof, it will be apparent to one skilled in the art that various changes and modifications can be made therein without departing from the spirit and scope :
thereof.
.
_ g , ~...
Claims (3)
1. A pharmaceutical composition for treating pigmentation for internal use which comprises tranexamic acid and ascorbic acid or a salt thereof both in an effective amount for treating pigmentation and a pharmaceutically acceptable carrier.
2. The pharmaceutical composition according to claim 1, wherein ascorbic acid or a salt thereof is contained in an amount of 0.3 to 2 parts by weight per part by weight of tranexamic acid.
3. The use of tranexamic acid and ascorbic acid or a salt thereof for preparation of a pharmaceutical composition for treating pigmentation.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP3023770A JPH04243825A (en) | 1991-01-25 | 1991-01-25 | Remedy for pigmentation |
| CA002086565A CA2086565A1 (en) | 1991-01-25 | 1992-12-31 | Pharmaceutical composition for treating pigmentation |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP3023770A JPH04243825A (en) | 1991-01-25 | 1991-01-25 | Remedy for pigmentation |
| CA002086565A CA2086565A1 (en) | 1991-01-25 | 1992-12-31 | Pharmaceutical composition for treating pigmentation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2086565A1 true CA2086565A1 (en) | 1994-07-01 |
Family
ID=25675787
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002086565A Abandoned CA2086565A1 (en) | 1991-01-25 | 1992-12-31 | Pharmaceutical composition for treating pigmentation |
Country Status (2)
| Country | Link |
|---|---|
| JP (1) | JPH04243825A (en) |
| CA (1) | CA2086565A1 (en) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004006908A1 (en) * | 2002-07-12 | 2004-01-22 | Hideyasu Takada | Remedies for pigmentation |
| WO2004060364A1 (en) | 2002-12-27 | 2004-07-22 | Daiichi Pharmaceutical Co., Ltd. | Skin lightening composition |
| US7947739B2 (en) | 2004-03-04 | 2011-05-24 | Ferring B.V. | Tranexamic acid formulations |
| US8022106B2 (en) | 2004-03-04 | 2011-09-20 | Ferring B.V. | Tranexamic acid formulations |
| US8273795B2 (en) | 2004-03-04 | 2012-09-25 | Ferring B.V. | Tranexamic acid formulations |
| US8957113B2 (en) | 2004-03-04 | 2015-02-17 | Ferring B.V. | Tranexamic acid formulations |
| US8968777B2 (en) | 2003-07-31 | 2015-03-03 | Ferring B.V. | Tranexamic acid formulations with reduced adverse effects |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1068868A3 (en) * | 1997-07-08 | 2001-01-31 | Rath, Matthias, Dr. med. | Synergistic compositions comprising ascorbate and lysine for states related to extracellular matrix degeneration |
| CH694549A5 (en) | 2001-01-16 | 2005-03-31 | Dr Matthias Rath | A composition comprising an ascorbate and a fibrinolysis inhibitor for treating diseases associated with extracellular matrix degradation e.g. arteriosclerosis, cancer, inflammations and infections |
| JPWO2006003965A1 (en) * | 2004-06-30 | 2008-04-17 | 第一三共ヘルスケア株式会社 | Whitening composition |
| WO2006023001A1 (en) * | 2004-07-30 | 2006-03-02 | Xanodyne Pharmaceuticals, Inc. | Tranexamic acid formulations |
| CN102105143B (en) | 2008-08-06 | 2013-03-20 | 第一三共健康事业株式会社 | Stable pharmaceutical composition containing tranexamic acid and ascorbic acid |
| KR101640958B1 (en) | 2008-09-05 | 2016-07-19 | 다이이찌 산쿄 헬스케어 가부시키가이샤 | Pharmaceutical solid preparation having active ingredients separated by boundary therein |
| MX340436B (en) * | 2008-09-12 | 2016-07-08 | Daiichi Sankyo Healthcare Co Ltd | Stable pharmaceutical formulation with limited discoloration. |
-
1991
- 1991-01-25 JP JP3023770A patent/JPH04243825A/en active Pending
-
1992
- 1992-12-31 CA CA002086565A patent/CA2086565A1/en not_active Abandoned
Cited By (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004006908A1 (en) * | 2002-07-12 | 2004-01-22 | Hideyasu Takada | Remedies for pigmentation |
| WO2004060364A1 (en) | 2002-12-27 | 2004-07-22 | Daiichi Pharmaceutical Co., Ltd. | Skin lightening composition |
| CN100335048C (en) * | 2002-12-27 | 2007-09-05 | 第一制药株式会社 | Skin-whitening composition |
| US8968777B2 (en) | 2003-07-31 | 2015-03-03 | Ferring B.V. | Tranexamic acid formulations with reduced adverse effects |
| US7947739B2 (en) | 2004-03-04 | 2011-05-24 | Ferring B.V. | Tranexamic acid formulations |
| US8022106B2 (en) | 2004-03-04 | 2011-09-20 | Ferring B.V. | Tranexamic acid formulations |
| US8273795B2 (en) | 2004-03-04 | 2012-09-25 | Ferring B.V. | Tranexamic acid formulations |
| US8487005B2 (en) | 2004-03-04 | 2013-07-16 | Ferring B.V. | Tranexamic acid formulations |
| US8791160B2 (en) | 2004-03-04 | 2014-07-29 | Ferring B.V. | Tranexamic acid formulations |
| US8809394B2 (en) | 2004-03-04 | 2014-08-19 | Ferring B.V. | Tranexamic acid formulations |
| US8957113B2 (en) | 2004-03-04 | 2015-02-17 | Ferring B.V. | Tranexamic acid formulations |
| US9060939B2 (en) | 2004-03-04 | 2015-06-23 | Ferring B.V. | Tranexamic acid formulations |
Also Published As
| Publication number | Publication date |
|---|---|
| JPH04243825A (en) | 1992-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2086565A1 (en) | Pharmaceutical composition for treating pigmentation | |
| RU93051780A (en) | CONTROLLED RELEASE COMPOSITIONS CONTAINING OXYCODONE, METHOD FOR REDUCING DAILY DOSES OF PRODUCTS CONTAINING OXYCODON | |
| HUT71889A (en) | Pharmaceutical compositions containing terfenadine metabolites and their optically pure isomers for treating allergic disorders | |
| CA2297834C (en) | Chromium/biotin treatment of type ii diabetes | |
| US4438138A (en) | Reduction of cholesterol with meta-chloro α-t-butylaminopropiophenone | |
| WO2020099926A1 (en) | A method for treating pulmonary arterial hypertension and associated pulmonary arterial hypertension | |
| DE19858789A1 (en) | Medicament combination of cerivastatin and fibrate, has additive effect in the treatment of lipid metabolism disorders, e.g. dyslipidemia or atherosclerosis | |
| CA2186867C (en) | Methods of using iron chelating compounds to reduce free radical damage in mammals | |
| JP4786127B2 (en) | Antipigmentation treatment | |
| US6017946A (en) | Serotonin containing formulation for oral administration and method of use | |
| KR900013969A (en) | Use of 5'-deoxy-5'-methylthioadenosine, S-adenosylmethionine and salts thereof and related pharmaceutical compositions in the manufacture of pharmaceutical compositions that reduce seborrhea | |
| JP2002145779A (en) | Composition for treatment or prophylaxis of arthralgia | |
| US20050043274A1 (en) | Pharmaceutical compositions and methods for lowering blood pressure and pulse rate | |
| JPH07330593A (en) | Improve for fatigue | |
| US4520132A (en) | Use of undecylenic acid to treat herpes labialis | |
| EP1150671B1 (en) | Use of pyrethroid compounds to promote hair growth | |
| EP0722325A1 (en) | Composition for the treatment or prevention of herpes | |
| JPH04342528A (en) | Agent for promotion of alcohol metabolism and acetaldehyde metabolism | |
| US4391809A (en) | Methods for treating psoriasis | |
| USRE32990E (en) | Use of undercylenic acid to treat herpes labialis | |
| JPH0680564A (en) | Anti-pigmentation agent | |
| HUP9900521A2 (en) | Process for preparing solid dosage forms of very low-dose drugs | |
| JP2000229853A (en) | Menstruation pain-improving composition | |
| JPH0753388A (en) | Bone metabolism improver | |
| GB2121277A (en) | Preparations for combating colds and flu, containing iron salt and calcium lactate |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Dead |